Business
Aptevo Therapeutics Provides a 1Q26 Business Update; RAINIER on Track for 2026 Completion and Phase 2 Dose Selection
Mipletamig continues to perform, delivers 87% clinical benefit and 81% remission in frontline AML, with no CRS in frontline patients Executive leadership transition complete. Jeff Lamothe appointed CEO; Marvin White assumes Executive Chair $60 million ...
About this update from Aptevo Therapeutics Inc.
[{"type":"text","content":"Mipletamig continues to perform, delivers 87% clinical benefit and 81% remission in frontline AML, with no CRS in frontline patients","length":132,"tagName":"p"},{"type":"text","content":"Executive leadership transition complete. Jeff Lamothe appointed CEO; Marvin White assumes Executive Chair","length":106,"tagName":"p"},{"type":"text","content":"$60 million equity line of credit enhances financial flexibility and extends access to capital through achievement of key catalysts into 2029","length":141,"tagName":"p"},{"type":"text","content":"SEATTLE, WA / ACCESS Newswire / May 13, 2026 / Aptevo Therapeutics Inc. (Nasdaq:APVO), a clinical-stage biotechnology company focused on developing novel immune-oncology therapeutics based on its proprietary ADAPTIR™ and ADAPTIR-FLEX™ platform technologies, today provided a business update.","length":291,"tagName":"p"},{"type":"text","content":""Aptevo is entering a defining period as a company, supported by growing clinical momentum, a committed leadership team, and a pipeline with the potential to create significant long-term value," said Jeff Lamothe, President and Chief Executive Officer of Aptevo. "Mipletamig continues to generate compelling frontline AML data, combining strong remission activity with a differentiated safety profile with the potential as an important addition to standard-of-care therapy. At the same time, we are continuing to advance our next generation of multispecific immunotherapy programs, including our emerging trispecific candidates, which are designed to address complex solid tumors through differentiated mechanisms and targeted immune modulation. We believe our ADAPTIR and ADAPTIR-FLEX platforms position Aptevo to expand into multiple high-value areas of oncology innovation. With meaningful clinical and strategic milestones ahead, financial flexibility to support execution, and increasing validation of multispecific approaches throughout the industry, we believe we are building from an increasingly strong foundation for future growth and value creation."","length":1181,"tagName":"p"},{"type":"text","content":"RAINIER trial on track for completion and Phase 2 dose selection by year end.","length":77,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Mipletamig continues to generate strong data in frontline acute myeloid le...